An interagency task force to fight coronavirus at the Siberian Branch of the Russian Academy of Sciences examined the first oral thrombolytic drug, Trombovazim, for use against the effects of COVID. It was reported by Olga Dorokhova, the executive secretary of the task force at the SB RAS.

      She noted that one of the main causes of high mortality of COVID-19 is associated pneumonia caused by coronavirus, and aggravating its course. In the process, a blood clot of fibrin protein is generated in the lungs and blood vessels.

      "That said, there is a new generation fibrinolytic in Russia - Trombovazim. Today, Trombovazim can be considered a target drug," - Olga Dorokhova said.

      Thrombovazim is able to gently inhibit both the formation of fibrin clots and thrombosis in capillaries.